Denali Therapeutics Inc
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-… Read more
Denali Therapeutics Inc (DNLI) - Total Assets
Latest total assets as of September 2025: $1.06 Billion USD
Based on the latest financial reports, Denali Therapeutics Inc (DNLI) holds total assets worth $1.06 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Denali Therapeutics Inc - Total Assets Trend (2015–2024)
This chart illustrates how Denali Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Denali Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Denali Therapeutics Inc's total assets of $1.06 Billion consist of 62.9% current assets and 37.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.7% |
| Accounts Receivable | $2.17 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Denali Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Denali Therapeutics Inc's current assets represent 62.9% of total assets in 2024, a decrease from 91.1% in 2015.
- Cash Position: Cash and equivalents constituted 12.7% of total assets in 2024, down from 83.8% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Denali Therapeutics Inc Competitors by Total Assets
Key competitors of Denali Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Denali Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Denali Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Denali Therapeutics Inc is currently not profitable relative to its asset base.
Denali Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.79 | 9.98 | 20.86 |
| Quick Ratio | 9.79 | 9.98 | 20.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $792.45 Million | $ 781.75 Million | $ 1.42 Billion |
Denali Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Denali Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.16 |
| Latest Market Cap to Assets Ratio | 2.01 |
| Asset Growth Rate (YoY) | 19.1% |
| Total Assets | $1.37 Billion |
| Market Capitalization | $2.76 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Denali Therapeutics Inc's assets at a significant premium ( 2.01x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Denali Therapeutics Inc's assets grew by 19.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Denali Therapeutics Inc (2015–2024)
The table below shows the annual total assets of Denali Therapeutics Inc from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.37 Billion | +19.09% |
| 2023-12-31 | $1.15 Billion | -20.98% |
| 2022-12-31 | $1.46 Billion | +3.99% |
| 2021-12-31 | $1.40 Billion | -12.47% |
| 2020-12-31 | $1.60 Billion | +189.98% |
| 2019-12-31 | $553.23 Million | -16.43% |
| 2018-12-31 | $661.98 Million | +36.01% |
| 2017-12-31 | $486.72 Million | +79.56% |
| 2016-12-31 | $271.07 Million | +638.94% |
| 2015-12-31 | $36.68 Million | -- |